Treatment for lower back pain poor, harmful globally: Lancet

Image
IANS Sydney
Last Updated : Mar 22 2018 | 6:10 PM IST

Current treatments including opioids, injections and surgery to treat lower back pain -- the leading cause of disability globally -- are useless, unnecessary and harmful, finds a series of studies in The Lancet.

Globally, lower back pain affects more than 540 million people and the condition has doubled in the last 25 years.

The prevalence of the condition is expected to continue to increase with an ageing and increasingly obese population.

Medical care with inappropriately high use of imaging, rest, opioids, spinal injections, and surgery is making the problem worse in both developed and developing countries, the findings showed.

"The burden from low back pain has reached a tipping point where the condition is growing rapidly, is poorly understood and is being mismanaged medically -- at cost both to the patient and to the healthcare system," said Rachelle Buchbinder, Professor at the Monash University in Melbourne.

"Low-and middle-income countries are already emulating the low-value care that is endemic in high-income countries.

"Across the globe (there is) inappropriately high use of imaging, rest, opioids, spinal injections and surgery. Doing more of the same will not reduce low back pain disability nor its long term consequences," Buchbinder said.

People with physically demanding jobs, physical and mental comorbidities, smokers, and obese individuals are at greatest risk of reporting low back pain.

The researchers call for a coordinated international leadership to drive transformational change across health and social services and occupational settings to stop fragmented and outdated models of care. They also call for avoidance of the harmful and useless medical treatments through the adoption of a similar framework to drug regulation.

Public health campaigns need to address the widespread population and health professional misconceptions about the causes and prognosis of low back pain and the effectiveness of different treatments.

--IANS

rt/qd/vm

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 22 2018 | 6:04 PM IST

Next Story